325 related articles for article (PubMed ID: 18035321)
1. Stimulatory autoantibodies to the PDGF receptor: a link to fibrosis in scleroderma and a pathway for novel therapeutic targets.
Gabrielli A; Svegliati S; Moroncini G; Luchetti M; Tonnini C; Avvedimento EV
Autoimmun Rev; 2007 Dec; 7(2):121-6. PubMed ID: 18035321
[TBL] [Abstract][Full Text] [Related]
2. Pathogenic autoantibodies in systemic sclerosis.
Gabrielli A; Svegliati S; Moroncini G; Avvedimento EV
Curr Opin Immunol; 2007 Dec; 19(6):640-5. PubMed ID: 18083509
[TBL] [Abstract][Full Text] [Related]
3. B lymphocytes: shedding new light on the pathogenesis of systemic sclerosis.
Hasegawa M
J Dermatol; 2010 Jan; 37(1):3-10. PubMed ID: 20175836
[TBL] [Abstract][Full Text] [Related]
4. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.
Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis.
Sakkas LI; Chikanza IC; Platsoucas CD
Nat Clin Pract Rheumatol; 2006 Dec; 2(12):679-85. PubMed ID: 17133253
[TBL] [Abstract][Full Text] [Related]
6. Fibrosis and immune dysregulation in systemic sclerosis.
Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of systemic sclerosis-current concept and emerging treatments.
Furue M; Mitoma C; Mitoma H; Tsuji G; Chiba T; Nakahara T; Uchi H; Kadono T
Immunol Res; 2017 Aug; 65(4):790-797. PubMed ID: 28488090
[TBL] [Abstract][Full Text] [Related]
8. T cells, B cells, and polarized immune response in the pathogenesis of fibrosis and systemic sclerosis.
Chizzolini C
Curr Opin Rheumatol; 2008 Nov; 20(6):707-12. PubMed ID: 18946333
[TBL] [Abstract][Full Text] [Related]
9. Role of PDGF in fibrotic diseases and systemic sclerosis.
Trojanowska M
Rheumatology (Oxford); 2008 Oct; 47 Suppl 5():v2-4. PubMed ID: 18784131
[TBL] [Abstract][Full Text] [Related]
10. The immunobiology of systemic sclerosis.
Gu YS; Kong J; Cheema GS; Keen CL; Wick G; Gershwin ME
Semin Arthritis Rheum; 2008 Oct; 38(2):132-60. PubMed ID: 18221988
[TBL] [Abstract][Full Text] [Related]
11. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease.
Svegliati S; Olivieri A; Campelli N; Luchetti M; Poloni A; Trappolini S; Moroncini G; Bacigalupo A; Leoni P; Avvedimento EV; Gabrielli A
Blood; 2007 Jul; 110(1):237-41. PubMed ID: 17363728
[TBL] [Abstract][Full Text] [Related]
12. B cells in systemic sclerosis: a possible target for therapy.
Bosello S; De Luca G; Tolusso B; Lama G; Angelucci C; Sica G; Ferraccioli G
Autoimmun Rev; 2011 Aug; 10(10):624-30. PubMed ID: 21545850
[TBL] [Abstract][Full Text] [Related]
13. Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology.
Dragun D; Distler JH; Riemekasten G; Distler O
Arthritis Rheum; 2009 Apr; 60(4):907-11. PubMed ID: 19333918
[No Abstract] [Full Text] [Related]
14. Induction of Scleroderma Fibrosis in Skin-Humanized Mice by Administration of Anti-Platelet-Derived Growth Factor Receptor Agonistic Autoantibodies.
Luchetti MM; Moroncini G; Jose Escamez M; Svegliati Baroni S; Spadoni T; Grieco A; Paolini C; Funaro A; Avvedimento EV; Larcher F; Del Rio M; Gabrielli A
Arthritis Rheumatol; 2016 Sep; 68(9):2263-73. PubMed ID: 27111463
[TBL] [Abstract][Full Text] [Related]
15. Molecular pathways as novel therapeutic targets in systemic sclerosis.
Trojanowska M; Varga J
Curr Opin Rheumatol; 2007 Nov; 19(6):568-73. PubMed ID: 17917537
[TBL] [Abstract][Full Text] [Related]
16. Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse.
Komura K; Fujimoto M; Yanaba K; Matsushita T; Matsushita Y; Horikawa M; Ogawa F; Shimizu K; Hasegawa M; Takehara K; Sato S
Ann Rheum Dis; 2008 Jun; 67(6):867-72. PubMed ID: 17823201
[TBL] [Abstract][Full Text] [Related]
17. Endothelin receptor selectivity: evidence from in vitro and pre-clinical models of scleroderma.
Shiwen X; Leask A; Abraham DJ; Fonseca C
Eur J Clin Invest; 2009 Jun; 39 Suppl 2():19-26. PubMed ID: 19335743
[TBL] [Abstract][Full Text] [Related]
18. Functional autoantibodies in systemic sclerosis pathogenesis.
Kill A; Riemekasten G
Curr Rheumatol Rep; 2015 May; 17(5):34. PubMed ID: 25876754
[TBL] [Abstract][Full Text] [Related]
19. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events.
Chizzolini C
Ann Med; 2007; 39(1):42-53. PubMed ID: 17364450
[TBL] [Abstract][Full Text] [Related]
20. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera.
Loizos N; Lariccia L; Weiner J; Griffith H; Boin F; Hummers L; Wigley F; Kussie P
Arthritis Rheum; 2009 Apr; 60(4):1145-51. PubMed ID: 19333919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
